<DOC>
	<DOCNO>NCT00124709</DOCNO>
	<brief_summary>This study consist 3-year double-blind phase patient receive atopic dermatitis ( AD ) treatment either pimecrolimus cream 1 % long-term management ( LTM ) conventional corticosteroid-based treatment ( 1:1 ratio ) , follow 2 3-year open-label ( OL ) phase ( patient receive pimecrolimus cream 1 % LTM ) . At end double-blind phase , two treatment group compare respect efficacy control AD ; end OL phase , incidence asthma age 6 year compare .</brief_summary>
	<brief_title>Safety Efficacy Pimecrolimus Cream 1 % Atopic Disease Modification</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Diagnosis atopic dermatitis Family history atopy 3 18 month age baseline At least mild atopic dermatitis baseline ( investigator global assessment [ IGA ] great equal 2 ) Clinical evidence atopic dermatitis longer 3 month Diagnosis substantial clinical evidence food allergy baseline Other protocol relate criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Atopic , dermatitis , asthma , child , modification</keyword>
	<keyword>Atopic dermatitis/atopy</keyword>
</DOC>